(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $44.56
Utstedt: 3 mai 2024 @ 21:45
Avkastning: 1.23%
Forrige signal: mai 3 - 19:02
Forrige signal:
Avkastning: 1.03 %
Live Chart Being Loaded With Signals
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer...
Stats | |
---|---|
Dagens volum | 1.49M |
Gjennomsnittsvolum | 1.20M |
Markedsverdi | 3.33B |
EPS | $-1.450 ( 2024-05-02 ) |
Neste inntjeningsdato | ( $-1.170 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.76 |
ATR14 | $2.98 (6.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ashar Bhavesh | Sell | 1 824 | Common Stock |
2024-02-16 | Pichl Daniel | Buy | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Stock Option (Right to Buy) |
2024-02-02 | Ashar Bhavesh | Sell | 1 089 | Common Stock |
INSIDER POWER |
---|
26.17 |
Last 99 transactions |
Buy: 2 487 277 | Sell: 1 935 911 |
Volum Korrelasjon
Springworks Therapeutics Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
PAE | 0.92 |
SY | 0.918 |
TIL | 0.917 |
CLBT | 0.916 |
FXCO | 0.915 |
SLN | 0.914 |
SCR | 0.914 |
CMPO | 0.914 |
TNYA | 0.913 |
ALGM | 0.911 |
10 Mest negative korrelasjoner | |
---|---|
BFRI | -0.916 |
TUEM | -0.915 |
VALN | -0.911 |
SVOK | -0.909 |
RTPY | -0.901 |
NAKD | -0.9 |
CYTO | -0.897 |
RMRM | -0.896 |
PROC | -0.895 |
LCAP | -0.883 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Springworks Therapeutics Korrelasjon - Valuta/Råvare
Springworks Therapeutics Økonomi
Annual | 2023 |
Omsetning: | $5.45M |
Bruttogevinst: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2023 |
Omsetning: | $5.45M |
Bruttogevinst: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2022 |
Omsetning: | $6.15M |
Bruttogevinst: | $4.25M (69.16 %) |
EPS: | $-5.14 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-4.02 |
Financial Reports:
No articles found.
Springworks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.